TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34284836

Group type: COMPARATOR
Intervention: TILS_dlPFC alone (n = 26)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Exposure + TILS_vmPFC (n = 29)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Exposure + sham TILS_vmPFC (n = 29)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Sham TILS_dlPFC alone (n = 28)
Number of subjects: 112
Study: 33338988

Group type: EXPERIMENTAL
Intervention: Stretching program (30 min/d, 5 d/wk for 8 wk)
Number of subjects: 40
Study: 32527152

Group type: EXPERIMENTAL
Intervention: Grading system for restaurant sanitation
Number of subjects: 0
Study: 35304401

Group type: EXPERIMENTAL
Intervention: Demanding albendazole
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Demanding amoxicillin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (not demanding any medicine)
Number of subjects: 200
Study: 32115311

Group type: EXPERIMENTAL
Intervention: Aggression Prevention Training (APT)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Enhanced Usual Primary Care (EU-PC)
Number of subjects: 228
Study: 33504434

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 8038

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 8038
Study: 32508327

Group type: EXPERIMENTAL
Intervention: Pridopidine 45 mg BID
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (historical control from 2CARE trial)
Number of subjects: 118
Study: 35896793

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33819217

Group type: EXPERIMENTAL
Intervention: Exer-gaming for 30 minutes twice a week for 8 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Balance training exercises twice a week for 8 weeks
Number of subjects: 90
Study: 36425335

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with transfer factor capsules
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cryotherapy with transfer factor capsules
Number of subjects: 61
Study: 34400956

Group type: COMPARATOR
Intervention: Oral betamethasone therapy (3 mg, once a week) with placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral methotrexate (15 mg, once a week) with placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate 15 mg, once a week and betamethasone 3 mg, once a week)
Number of subjects: 36
Study: 36226802

Group type: EXPERIMENTAL
Intervention: Intralesional combined furosemide and digoxin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intralesional normal saline solution (Control)
Number of subjects: 80
Study: 33639493

Group type: EXPERIMENTAL
Intervention: Monopolar electrocautery
Number of subjects: 103

Group type: COMPARATOR
Intervention: Plasma ablation
Number of subjects: 103
Study: 33724296

Group type: EXPERIMENTAL
Intervention: 5 × 5 Gy radiotherapy and two cycles of XELOX (arm A)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Chemoradiotherapy with concurrent capecitabine (arm B)
Number of subjects: 140
Study: 32650732

Group type: EXPERIMENTAL
Intervention: Community Assets Supporting Transitions (CAST) intervention
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 216
Study: 33603097

Group type: EXPERIMENTAL
Intervention: Organic carbon exposure (increase of 0.51 μg/m3)
Number of subjects: 83454

Group type: EXPERIMENTAL
Intervention: Sodium exposure (increase of 0.06 μg/m3)
Number of subjects: 83454

Group type: EXPERIMENTAL
Intervention: Ozone exposure
Number of subjects: 83454
Study: 32339262

Group type: EXPERIMENTAL
Intervention: BaPoFi-TTE method for analyzing time-to-event data with censoring and toxicity outcomes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BaPoFi method for population finding with continuous or binary outcomes.
Number of subjects: 0
Study: 32820320

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18918

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18918
Study: 35001643

Group type: EXPERIMENTAL
Intervention: Active non-invasive vagus nerve stimulation
Number of subjects: 336

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 336
Study: 32706716

Group type: EXPERIMENTAL
Intervention: Intervention app (n=73)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Active control app (n=110)
Number of subjects: 183
Study: 35974347

Group type: EXPERIMENTAL
Intervention: Guided online group singing (1 session per week for 12 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 100
Study: 34304913

Group type: EXPERIMENTAL
Intervention: FDC IBU/APAP 250 mg/500 mg
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: IBU 250 mg
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: APAP 500 mg
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: FDC IBU/APAP 250 mg/500 mg, IBU 250 mg, APAP 500 mg
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: IBU cohort
Number of subjects: 290

Group type: COMPARATOR
Intervention: FDC IBU/APAP 250 mg/500 mg, placebo
Number of subjects: 290
Study: 32423576

Group type: EXPERIMENTAL
Intervention: Intravenous TXA (1 g + 0.9% normal saline 100 mL)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Topical TXA (2 g + 0.9% normal saline 50 mL)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combined TXA
Number of subjects: 102
Study: 34262263

Group type: EXPERIMENTAL
Intervention: AMPH ER TAB (amphetamine extended-release tablet)
Number of subjects: 35
Study: 33089769

Group type: EXPERIMENTAL
Intervention: TACE combined with anlotinib (TC group)
Number of subjects: 82

Group type: COMPARATOR
Intervention: TACE alone (TA group)
Number of subjects: 82
Study: 32957900

Group type: EXPERIMENTAL
Intervention: Resistance exercise program (REP, 50‐60% of 1RM, for 40‐50 min) combined with metformin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (AEP, 50‐70% maxHR, for 40‐50 min) combined with metformin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Metformin without exercise intervention (Met group)
Number of subjects: 57
Study: 33040806

Group type: EXPERIMENTAL
Intervention: Esomeprazole plus flupenthixol/melitracen
Number of subjects: 140

Group type: COMPARATOR
Intervention: Esomeprazole
Number of subjects: 140
Study: 35420554

Group type: EXPERIMENTAL
Intervention: Combination prevention (CP) including intensive testing, linkage campaigns, expanded ART, and voluntary male medical circumcision referrals
Number of subjects: 55000

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 55000
Study: 34620454

Group type: EXPERIMENTAL
Intervention: Fast Track and Standard Treatment Trial (FASTT)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Trying to conceive without treatment
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Autologous oocyte in vitro fertilization
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Overall outcomes after FASTT
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Overall reproductive outcomes
Number of subjects: 286
Study: 33684737

Group type: EXPERIMENTAL
Intervention: n−3 PUFA (2.2 g/day)
Number of subjects: 71
Study: 33741075

Group type: EXPERIMENTAL
Intervention: SeqEnhDL deep learning framework
Number of subjects: 9
Study: 33337602

Group type: EXPERIMENTAL
Intervention: Cam-type FAI patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Unilateral FAI patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control patients (asymptomatic hips)
Number of subjects: 16
Study: 33007299

Group type: COMPARATOR
Intervention: Depot medroxyprogesterone acetate (DMPA) users
Number of subjects: 3

Group type: COMPARATOR
Intervention: Pregnant women
Number of subjects: 3

Group type: COMPARATOR
Intervention: Non-pregnant women not using hormonal or intrauterine contraception
Number of subjects: 3
Study: 33884767

Group type: EXPERIMENTAL
Intervention: CK-30
Number of subjects: 0

Group type: COMPARATOR
Intervention: Red ginseng extract
Number of subjects: 0
Study: 33571959

Group type: EXPERIMENTAL
Intervention: Concurrent endurance and strength training (n = 14)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Endurance training only (n = 11)
Number of subjects: 25
Study: 35029748

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy with phycocyanin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy with toluidine blue O
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Total-etch groups with aPDT
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control total etch groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups after thermocycling
Number of subjects: 60
Study: 34083582

Group type: EXPERIMENTAL
Intervention: Land-use change and topography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictive maps of larval habitats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk factor analyses
Number of subjects: 0
Study: 32576004

Group type: EXPERIMENTAL
Intervention: WeChat group (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional group (n=20)
Number of subjects: 40
Study: 35296483

Group type: COMPARATOR
Intervention: Control message (Your coronavirus test result is negative)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Current NHS Test & Trace message (Your coronavirus test result is negative + Its likely you were not infectious when the test was done)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Elaborated NHS T&T message (Your coronavirus test result is negative + Its likely you were not infectious when the test was done + But there is still a chance you may be infectious)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Elaborated NHS T&T+infographic message (Your coronavirus test result is negative + Its likely you were not infectious when the test was done + But there is still a chance you may be infectious + infographic depicting residual risk)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: All messages (including control)
Number of subjects: 1200
Study: 33136005

Group type: EXPERIMENTAL
Intervention: Biodegradable-polymer biolimus-eluting stents (BP-BES)
Number of subjects: 2712

Group type: COMPARATOR
Intervention: Durable-polymer everolimus-eluting stents (DP-EES)
Number of subjects: 2712

Group type: COMPARATOR
Intervention: Durable-polymer zotarolimus-eluting stents (DP-ZES)
Number of subjects: 2712
Study: 36011692

Group type: EXPERIMENTAL
Intervention: Pharmacist-Based Diabetic Intervention (PDIM)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 109
Study: 33373976

Group type: EXPERIMENTAL
Intervention: Ankle mobilization with anterior tibia glide
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Ankle mobilization with posterior tibia glide
Number of subjects: 117

Group type: COMPARATOR
Intervention: Ankle mobilization with anterior and posterior tibia glide
Number of subjects: 117
Study: 35871490

Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin (1.5 mg/ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intralesional triamcinolone (20 mg/ml)
Number of subjects: 60
Study: 33840229

Group type: EXPERIMENTAL
Intervention: Benralizumab single dose (30 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Benralizumab q4w (30 mg every 4 weeks for a total of three doses)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Benralizumab (both dosing regimens)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Benralizumab (in patients with high blood eosinophil levels)
Number of subjects: 56
Study: 32275368

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with conventional symptomatic and supportive treatments
Number of subjects: 68

Group type: COMPARATOR
Intervention: Symptomatic and supportive treatments (control group)
Number of subjects: 68
Study: 35114800

Group type: EXPERIMENTAL
Intervention: Neoadjuvant intraperitoneal‐systemic chemotherapy
Number of subjects: 238

Group type: COMPARATOR
Intervention: Paclitaxel + S‐1 (PS) chemotherapy
Number of subjects: 238
Study: 33026517

Group type: EXPERIMENTAL
Intervention: 10 mg ICG injection at 8 hours prior to surgery
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 10 mg ICG injection at 10 hours prior to surgery
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 10 mg ICG injection at 12 hours prior to surgery
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 10 mg ICG injection at 14 hours prior to surgery
Number of subjects: 29
Study: 36364825

Group type: EXPERIMENTAL
Intervention: Live Lactobacillus paracasei (L-PS23, 2 × 10^10 CFU/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heat-killed Lactobacillus paracasei (HK-PS23, 2 × 10^10 cells/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32997229

Group type: EXPERIMENTAL
Intervention: Social network density
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Social network size
Number of subjects: 94
Study: 35442179

Group type: EXPERIMENTAL
Intervention: HCP Plus Peer Support
Number of subjects: 292

Group type: COMPARATOR
Intervention: HCP Support
Number of subjects: 292
Study: 32046568

Group type: EXPERIMENTAL
Intervention: High breath alcohol concentration (BAC) group (≥0.08)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Moderate breath alcohol concentration (BAC) group (≤0.08)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Sober group
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control condition (juice)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: High BAC group (≥0.08)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Moderate BAC group (≤0.08)
Number of subjects: 137
Study: 36044215

Group type: EXPERIMENTAL
Intervention: AI-aided interpretation
Number of subjects: 497
Study: 33313808

Group type: EXPERIMENTAL
Intervention: Definitions retrieved from the Delphi-like method
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intra-observer agreement for SU
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intra-observer agreement for AE
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intra-observer agreement for DU
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intra-observer agreement for any ulceration (DU or SU)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for SU
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for AE
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for DU
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for any ulceration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for high-quality videos (DU)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for high-quality videos (AE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for high-quality videos (any ulceration)
Number of subjects: 30
Study: 35235198

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG): 40–45 kcal and 1.5 g protein/kg/day; diet plus polymeric formula
Number of subjects: 104
Study: 34202877

Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride (3000 mg GlucosaGreen®)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Maltodextrin placebo
Number of subjects: 11
Study: 32327366

Group type: EXPERIMENTAL
Intervention: Deep dry needling
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham dry needling
Number of subjects: 24
Study: 35249488

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (60 minutes, three times per week for 16 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 45
Study: 33691739

Group type: EXPERIMENTAL
Intervention: Deep learning-based fully-automatic DENSE strain analysis
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Deep learning-based phase unwrapping U-Net
Number of subjects: 64

Group type: COMPARATOR
Intervention: Deep learning-based fully-automatic global and segmental circumferential strain analysis
Number of subjects: 64
Study: 36424008

Group type: EXPERIMENTAL
Intervention: Tofogliflozin (20 mg/d)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Anagliptin (200 mg/d)
Number of subjects: 80
Study: 33940625

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Well-rested control condition
Number of subjects: 68
Study: 32172292

Group type: EXPERIMENTAL
Intervention: Constant learning
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Variable learning
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 34802140

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no block)
Number of subjects: 78
Study: 34895357

Group type: EXPERIMENTAL
Intervention: Integration of HIV risk screening and PrEP delivery in public health family planning clinics, delivered by existing FP clinic staff with training and technical assistance.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Core multifaceted implementation strategies including health provider training and stakeholder engagement.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard care service package including screening for HIV risk, HIV testing, dispensing, adherence and risk reduction counseling, assessment of side effects, and provision of refills.
Number of subjects: 0
Study: 34952965

Group type: EXPERIMENTAL
Intervention: Obturator Nerve Block (ONB)
Number of subjects: 0
Study: 32977221

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Independent-assessed RECIST
Number of subjects: 275
Study: 36067615

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily) plus bevacizumab (15 mg/kg every 3 weeks) for up to 24 months and 15 months respectively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus bevacizumab (15 mg/kg every 3 weeks) for up to 15 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily) plus bevacizumab (15 mg/kg every 3 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus bevacizumab (15 mg/kg every 3 weeks)
Number of subjects: 0
Study: 33789008

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg every 2 weeks for 16 weeks, followed by 480 mg every 4 weeks)
Number of subjects: 794

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 794
Study: 35106400

Group type: EXPERIMENTAL
Intervention: Capacity-building intervention including a structured toolkit and technical-assistance calls
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control arm (no specific intervention mentioned)
Number of subjects: 20
Study: 33336427

Group type: EXPERIMENTAL
Intervention: Effective supervision model implemented by the Ministry of Health and Population (MOHP) at central, governorate, and district levels.
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Standardized consistent checklist used by supervisors for service delivery.
Number of subjects: 500
Study: 35584106

Group type: EXPERIMENTAL
Intervention: Vibration Foam Roller (VFR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Portable Vibration Percussion Device (PVPD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 33542046

Group type: EXPERIMENTAL
Intervention: iSelf-help (online-delivered PMP)
Number of subjects: 180

Group type: COMPARATOR
Intervention: In-person PMP (control group)
Number of subjects: 180
Study: 35387943

Group type: EXPERIMENTAL
Intervention: Surgical intervention (clipping)
Number of subjects: 1863

Group type: COMPARATOR
Intervention: Endovascular treatment (coiling)
Number of subjects: 1863
Study: 33828257

Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32713850

Group type: EXPERIMENTAL
Intervention: Self-directed multimedia consent process
Number of subjects: 298

Group type: COMPARATOR
Intervention: Traditional paper-based consent process
Number of subjects: 298
Study: 34969541

Group type: EXPERIMENTAL
Intervention: Cholvax (Incepta Vaccine Ltd)
Number of subjects: 2052
Study: 33026142

Group type: EXPERIMENTAL
Intervention: Short acting BP medication added in the evening
Number of subjects: 33

Group type: COMPARATOR
Intervention: No medication change (control)
Number of subjects: 33
Study: 35236080

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-Fluorouracil (5-FU)
Number of subjects: 0
Study: 33024323

Group type: EXPERIMENTAL
Intervention: Fibrin glue (FG)‐assisted mucous membrane grafting (MMG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuous 8‐0 polygalactin suture (PS)‐assisted mucous membrane grafting (MMG)
Number of subjects: 20
Study: 33263357

Group type: EXPERIMENTAL
Intervention: Physician/Personal (PP) message
Number of subjects: 2007

Group type: COMPARATOR
Intervention: Federal/Impersonal (FI) message
Number of subjects: 2007
Study: 35255880

Group type: EXPERIMENTAL
Intervention: Barberry (10 g/day dried barberry)
Number of subjects: 84
Study: 34169420

Group type: EXPERIMENTAL
Intervention: Support Vector Regression (SVR) model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple Regression (MR) model
Number of subjects: 0
Study: 32339447

Group type: EXPERIMENTAL
Intervention: hIL-7-hyFc (20, 60 μg/kg s.c. or 60 μg/kg i.m.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 35867702

Group type: EXPERIMENTAL
Intervention: PegIFN alfa‐2a (180 μg/week) for 48 weeks
Number of subjects: 149

Group type: COMPARATOR
Intervention: Nucleos(t)ide analogue (NA) for 48 weeks
Number of subjects: 149
Study: 33561041

Group type: EXPERIMENTAL
Intervention: Forest Therapy (FT) intervention
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control period (10 weeks)
Number of subjects: 140
Study: 34184165

Group type: EXPERIMENTAL
Intervention: Immediate loading (IL)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional loading (CL)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both IL and CL groups
Number of subjects: 19